Curcumin is a naturally occurring polyphenol compound
with potential
analgesic effects. It has been shown to improve pain-like behaviors
in numerous models of pain. Despite its potential, curcumin exhibits
poor physicochemical and pharmacokinetic properties, which hinder
its oral therapeutic efficacy. Curcumin diethyl γ-aminobutyrate
(CUR-2GE), a carbamate prodrug of curcumin, was designed to overcome
these limitations and demonstrated greater anti-neuroinflammatory
effects compared to curcumin in vitro. Thus, this
study evaluated the effect of CUR-2GE and its parent compound on pain-like
behaviors in carrageenan- and LPS-induced mouse models. The possible
side effects of CUR-2GE were also assessed by exploring its effects
on motor coordination and spontaneous locomotor activity after acute
and chronic treatments. The results showed that CUR-2GE improved mechanical
and thermal hyperalgesia and locomotor activity to a greater extent
than curcumin in carrageenan-induced mice. These results are in line
with the ability of CUR-2GE to suppress peripheral inflammation in
the paw tissue of carrageenan-induced mice, indicated by a significant
decrease in TNF-α and IL-6 expression levels. Similarly, in
LPS-induced mice, CUR-2GE improved sickness and pain-like behaviors
(exploratory behaviors and long-term locomotor activity) to a greater
extent than curcumin. Furthermore, CUR-2GE significantly reduced the
level of proinflammatory cytokines in both the plasma and spinal cord
tissue of LPS-induced mice, exhibiting significantly higher inhibition
than curcumin. Moreover, the motor coordination, and locomotive behaviors
of mice were not affected by both acute and chronic administration
of CUR-2GE, indicating no potential CNS side effects. Thus, CUR-2GE
demonstrated enhanced therapeutic efficacy in mouse models of inflammatory
pain without any possible CNS side effects, suggesting its potential
to be developed as an analgesic agent against inflammatory pain.